Article citationsMore>>

Gul, A., Tugal-Tutkun, I., Dinarello, C.A., Reznikov, L., Esen, B.A., Mirza, A., et al. (2012) Interleukin-1betaregulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: An open-label pilot study. Annals of the Rheumatic Diseases, 71, 563-566. doi:10.1136/annrheumdis-2011-155143

has been cited by the following article:

• TITLE: Biological agents in the treatment of uveitis

  AUTHORS: Maria Pia Paroli, Alessandro Abbouda, Irene Abicca, Alfredo Sapìa, Marino Paroli

  KEYWORDS: Biologics; Uveitis

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.8B, August 8, 2013

  ABSTRACT: Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biological process and therefore defined as “biologics” has been successfully used in the treatment of immunemediated rheumatic diseases. These drugs target different pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small uncontrolled trials, with general and unexpected efficacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheumatic diseases. We used PubMed search engine as the main source of information. Among the papers included in the reference list, a particular emphasis was given on articles published during the last 5 years.